e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Current issues in malignant pleural diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic significance of neutrophil predominance in pleural fluid in patients with malignant effusion
R. M. Díaz Campos, V. Villena Garrido, M. D. Hisado Díaz, I. Escribano Gimeno, A. López Encuentra (Madrid, Spain)
Source:
Annual Congress 2010 - Current issues in malignant pleural diseases
Session:
Current issues in malignant pleural diseases
Session type:
Thematic Poster Session
Number:
3323
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. M. Díaz Campos, V. Villena Garrido, M. D. Hisado Díaz, I. Escribano Gimeno, A. López Encuentra (Madrid, Spain). Prognostic significance of neutrophil predominance in pleural fluid in patients with malignant effusion. Eur Respir J 2010; 36: Suppl. 54, 3323
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Significance of macrophage predominance in pleural effusions
Source: Annual Congress 2003 - Pleural effusion
Year: 2003
Is it important to determine pleural fluid amylase in patients with malignant pleural effusions?
Source: Eur Respir J 2007; 30: Suppl. 51, 565s
Year: 2007
Utility of pleural fluid for predictive marker testing in malignant pleural effusion
Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications
Year: 2020
Correlation between pleural fluid cytological yield and pleural tumour burden in malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
Prognostic features of residual pleural thickening after parapneumonic pleural effusion
Source: Eur Respir J 2002; 20: Suppl. 38, 605s
Year: 2002
Accuracy of pleural fluid c-reactive protein in differentiating between tuberculous and malignant pleural effusions: a meta-analysis
Source: International Congress 2019 – Tuberculosis and comorbidities
Year: 2019
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma
Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions
Year: 2012
Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy
Source: Annual Congress 2011 - From outside to inside: access to the pleura
Year: 2011
Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma
Source: Eur Respir J 2006; 28: Suppl. 50, 784s
Year: 2006
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM)
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Cytology of pleural fluid versus histopathology of the pleura in the diagnosis of malignant pleural effusions
Source: Eur Respir J 2006; 28: Suppl. 50, 775s
Year: 2006
Evaluation of patients with pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 247s
Year: 2004
Value of pleural fluid and serum NT-ProBNP levels in differentiation of transudative and exudative pleural effusions
Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions
Year: 2010
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM)
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Diagnostic accuracy of pleural fluid NTpro-BNP for pleural effusions of cardiac origin
Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura
Year: 2012
Diagnostic and prognostic significance of survivin levels in malignant pleural effusion
Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Year: 2011
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Pleural fluid, serum β-HCG levels and pleural fluid/serum β-HCG ratio for the discrimination of malignant and benign pleural effusions
Source: Eur Respir J 2003; 22: Suppl. 45, 60s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept